Serumuric acidandthe riskof cardiovascular and renal disease

Claudio Borghi, Enrico Agabiti Rosei, Thomas Bardin, Jesse Dawson, Anna Dominiczak, Jan T. Kielstein, Athanasios J. Manolis, Fernando Perez-Ruiz, Giuseppe Mancia

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.

Original languageEnglish
Pages (from-to)1729-1741
Number of pages13
JournalJournal of Hypertension
Volume33
Issue number9
DOIs
Publication statusPublished - 2015

Fingerprint

Uric Acid
Cardiovascular Diseases
Kidney
Hyperuricemia
Gout
Chronic Renal Insufficiency
Xanthine Oxidase
Serum
Therapeutics
Hypertension
Pharmaceutical Preparations

Keywords

  • Cardiovascular disease
  • Hyperuricemia
  • Renal disease
  • Serum uric acid

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Borghi, C., Rosei, E. A., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J. T., ... Mancia, G. (2015). Serumuric acidandthe riskof cardiovascular and renal disease. Journal of Hypertension, 33(9), 1729-1741. https://doi.org/10.1097/HJH.0000000000000701

Serumuric acidandthe riskof cardiovascular and renal disease. / Borghi, Claudio; Rosei, Enrico Agabiti; Bardin, Thomas; Dawson, Jesse; Dominiczak, Anna; Kielstein, Jan T.; Manolis, Athanasios J.; Perez-Ruiz, Fernando; Mancia, Giuseppe.

In: Journal of Hypertension, Vol. 33, No. 9, 2015, p. 1729-1741.

Research output: Contribution to journalArticle

Borghi, C, Rosei, EA, Bardin, T, Dawson, J, Dominiczak, A, Kielstein, JT, Manolis, AJ, Perez-Ruiz, F & Mancia, G 2015, 'Serumuric acidandthe riskof cardiovascular and renal disease', Journal of Hypertension, vol. 33, no. 9, pp. 1729-1741. https://doi.org/10.1097/HJH.0000000000000701
Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al. Serumuric acidandthe riskof cardiovascular and renal disease. Journal of Hypertension. 2015;33(9):1729-1741. https://doi.org/10.1097/HJH.0000000000000701
Borghi, Claudio ; Rosei, Enrico Agabiti ; Bardin, Thomas ; Dawson, Jesse ; Dominiczak, Anna ; Kielstein, Jan T. ; Manolis, Athanasios J. ; Perez-Ruiz, Fernando ; Mancia, Giuseppe. / Serumuric acidandthe riskof cardiovascular and renal disease. In: Journal of Hypertension. 2015 ; Vol. 33, No. 9. pp. 1729-1741.
@article{edc2a5f7e95c46669e70e62d3cc6b126,
title = "Serumuric acidandthe riskof cardiovascular and renal disease",
abstract = "Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.",
keywords = "Cardiovascular disease, Hyperuricemia, Renal disease, Serum uric acid",
author = "Claudio Borghi and Rosei, {Enrico Agabiti} and Thomas Bardin and Jesse Dawson and Anna Dominiczak and Kielstein, {Jan T.} and Manolis, {Athanasios J.} and Fernando Perez-Ruiz and Giuseppe Mancia",
year = "2015",
doi = "10.1097/HJH.0000000000000701",
language = "English",
volume = "33",
pages = "1729--1741",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Serumuric acidandthe riskof cardiovascular and renal disease

AU - Borghi, Claudio

AU - Rosei, Enrico Agabiti

AU - Bardin, Thomas

AU - Dawson, Jesse

AU - Dominiczak, Anna

AU - Kielstein, Jan T.

AU - Manolis, Athanasios J.

AU - Perez-Ruiz, Fernando

AU - Mancia, Giuseppe

PY - 2015

Y1 - 2015

N2 - Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.

AB - Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular diseases. This highlights the need for greater attention to serum uric acid levels when profiling patients, and suggests that the threshold above which uricemia is considered abnormal is 6 mg/dl, in light of the available evidence. Another important question is whether lowering serum uric acid can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients; the available literature shows a trend toward improvement associated with administration of urate-lowering drugs, in particular for the xanthine oxidase inhibitors. The demonstrated efficacy of urate-lowering therapy on outcomes other than gout flares leads to the consideration that treatment may be beneficial even in the absence of overt gout when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced CKD or cardiovascular risk factors.

KW - Cardiovascular disease

KW - Hyperuricemia

KW - Renal disease

KW - Serum uric acid

UR - http://www.scopus.com/inward/record.url?scp=84942589687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942589687&partnerID=8YFLogxK

U2 - 10.1097/HJH.0000000000000701

DO - 10.1097/HJH.0000000000000701

M3 - Article

C2 - 26136207

AN - SCOPUS:84942589687

VL - 33

SP - 1729

EP - 1741

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 9

ER -